Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
(WorldNews Health)

Press Release Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc. OSAKA, Japan, October 11, 2019 - Shionogi & Co., Ltd. (Head Office: Osaka; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. (Head Office: Media, PA, USA; President and CEO: William Claypool, M.D.; hereafter "Hsiri") regarding a collaborative research and development program to discover and develop additional novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB). This...